Brimonidine Tartrate a Safe and Effective API for Reducing Pressure Behind the Eye

Brimonidine Tartrate a Safe and Effective API for Reducing Pressure Behind the Eye

Brimonidine Tartrate
Drug Research & Development API

Brimonidine Tartrate CAS No: 79570-19-7

Known for treating open-angle glaucoma, brimonidine tartrate is a safe and effective API for reducing pressure behind the eye. The medication allows better drainage of fluids to both relieve patient suffering and protect eyes from further damage. High-fluid pressure can cause anything from mild nerve damage to total blindness. However, brimonidine tartrate is also known for being a vasoconstrictor, which can help with skin conditions, such as rosacea. Furthermore, studies also suggest that this API may be useful for treating general redness with unknown origins better than traditional solutions on the market.

Glaucoma Success

Brimonidine is an apha2-adrenergic receptor that has been used to treat both open-angle and ocular hypertension. Doctors have seen success using it as the sole therapy, but it can also be in combination with other medications as well an in replacement therapy. Brimonidine is often combined with other APIs to strengthen results, including timolol and latanoprost. But whether it’s the star of the show or not, it’s been an effective choice for glaucoma patients everywhere. The best absorption rates occur in forms of brimonidine with higher pH balances, while the best tolerance for patients is for forms with the lowest available concentrations. Treatments consistently lower the interocular pressure of patients without adverse side effects. Independent from its reduction of pressure though, there is also evidence to suggest that brimonidine tartrate may be able to protect the retinal ganglion cells. These cells typically die by apoptosis in the case of glaucoma, but this beneficial API may be able to keep those cells healthier longer.

Chronic Redness

Eye redness is a common condition that plagues 6.5 million Americans. While it may not be life-threatening, it can be uncomfortable or embarrassing in work or social situations. While there are a number of decongestants available for those who have occasional or chronic eye redness, long-term use of other vasoconstrictors may pose safety risks to users. Not only is rebound redness a common complaint, but so is the possibility of tachyphylaxis. In one randomized clinical trial, 60 patients were given either brimonidine tartrate or a topical comparison. Those who received the brimonidine showed significantly reduced redness compared to the control group. These benefits were seen over the course of the entire trial, with a low chance of rebound redness. The authors of the report concluded that this API might be a better choice when it comes to treating chronic sufferers of red-eye. Side effects tend to be mild, but include stinging of the eyes, blurred vision, as well as headaches and nausea.

Skin Conditions

In 2013, the FDA approved brimonidine tartrate to be used for skin conditions that cause facial flushing. Most notably, those who have both rosacea and facial erythema have turned to this topical gel to reverse the effects of vasodilation. This condition affects up to 40 million people all over the world, and clinical trials have shown that brimonidine tartrate may provide better efficacy than the most popular treatment methods on the market. Researchers were primarily encouraged by how quickly the substance was able to reduce the worst of symptoms. It also not only remained effective throughout the day but also maintained an excellent safety profile for up to a full year after treatment. Unfortunately, brimonidine tartrate has been linked to rebound redness for some patients though.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in the distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities, expert regulatory support as well as other value-added services.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service